CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Restructuring Reserve, Translation and Other Adjustment
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) reported Restructuring Reserve, Translation and Other Adjustment of $1.83 million for the 12-month period ending 2021-12-25, per its 10-K filed 2022-02-16.
Discontinued › Notes › Restructuring and Related Activities
us-gaap:RestructuringReserveTranslationAndOtherAdjustment · last filed 2022-02-16
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring reserve, translation and other adjustment for the quarter ending 2021-12-25 was $0.00.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring reserve, translation and other adjustment for the quarter ending 2021-09-25 was $0.00.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring reserve, translation and other adjustment for the quarter ending 2021-06-26 was $0.00.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring reserve, translation and other adjustment for the quarter ending 2021-03-27 was $1.83M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring reserve, translation and other adjustment for fiscal 2021 was $1.83M.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring reserve, translation and other adjustment for fiscal 2020 was $0.00.
- CHARLES RIVER LABORATORIES INTERNATIONAL, INC. restructuring reserve, translation and other adjustment for fiscal 2019 was $0.00.
| Period end | Restructuring Reserve, Translation and Other Adjustment 3 month | Restructuring Reserve, Translation and Other Adjustment 6 month | Restructuring Reserve, Translation and Other Adjustment 9 month | Restructuring Reserve, Translation and Other Adjustment 12 month |
|---|---|---|---|---|
| 2021-12-25 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $0.00 derived: sum of 2 quarters · filed 2022-02-16 | $0.00 derived: sum of 3 quarters · filed 2022-02-16 | $1.83M 10-K · filed 2022-02-16 |
| 2021-09-25 | $0.00 10-Q · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $1.83M 10-Q · filed 2021-11-03 | $1.83M derived: sum of 4 quarters · filed 2022-02-16 |
| 2021-06-26 | $0.00 10-Q · filed 2021-08-04 | $1.83M 10-Q · filed 2021-08-04 | $1.83M derived: sum of 3 quarters · filed 2022-02-16 | $1.83M derived: sum of 4 quarters · filed 2022-02-16 |
| 2021-03-27 | $1.83M 10-Q · filed 2021-05-04 | $1.83M derived: sum of 2 quarters · filed 2022-02-16 | $1.83M derived: sum of 3 quarters · filed 2022-02-16 | $1.83M derived: sum of 4 quarters · filed 2022-02-16 |
| 2020-12-26 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-16 | $0.00 derived: sum of 2 quarters · filed 2022-02-16 | $0.00 derived: sum of 3 quarters · filed 2022-02-16 | $0.00 10-K · filed 2022-02-16 |
| 2020-09-26 | $0.00 10-Q · filed 2021-11-03 | $0.00 derived: sum of 2 quarters · filed 2021-11-03 | $0.00 10-Q · filed 2021-11-03 | |
| 2020-06-27 | $0.00 10-Q · filed 2021-08-04 | $0.00 10-Q · filed 2021-08-04 | ||
| 2020-03-28 | $0.00 10-Q · filed 2021-05-04 | |||
| 2019-12-28 | $0.00 10-K · filed 2022-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |